+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Myeloma Therapeutics Market by Drug Class, Treatment Line, Mode of Administration, Distribution Channel, Product Type - Global Forecast to 2030- Product Image
Multiple Myeloma Therapeutics Market by Drug Class, Treatment Line, Mode of Administration, Distribution Channel, Product Type - Global Forecast to 2030- Product Image
Sale

Multiple Myeloma Therapeutics Market by Drug Class, Treatment Line, Mode of Administration, Distribution Channel, Product Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674082
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Multiple Myeloma Therapeutics Market grew from USD 22.95 billion in 2024 to USD 24.60 billion in 2025. It is expected to continue growing at a CAGR of 7.16%, reaching USD 34.76 billion by 2030.

Navigating the Evolution of Multiple Myeloma Treatment

Multiple myeloma remains a formidable challenge in oncology, yet the therapeutic landscape has transformed dramatically in recent years. Breakthrough innovations have expanded treatment modalities beyond traditional chemotherapy and stem cell transplant, ushering in a new era of precision medicine and cellular therapies. This executive summary offers a concise yet comprehensive overview of the key drivers shaping market dynamics, regulatory influences, segmentation nuances, regional performance, and competitive strategies.

In preparing this analysis, rigorous research methodologies have been applied to ensure that decision-makers gain actionable insights into pivotal trends and emerging opportunities. By synthesizing primary expert interviews, clinical data, and secondary intelligence, this report illuminates critical inflection points and equips stakeholders with the strategic context needed to navigate an increasingly complex environment.

Transformative Shifts Redefining the Therapeutic Terrain

The multiple myeloma arena has witnessed transformative shifts that redefine therapeutic expectations and patient outcomes. Foremost among these is the advent of CAR-T cell therapies, which reprogram a patient’s own immune cells to target malignant plasma cells with unprecedented specificity. Early approvals of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel have catalyzed further investment in cellular and gene-based interventions.

Simultaneously, the maturation of bispecific antibody platforms and next-generation monoclonal antibodies is expanding the arsenal against resistant disease. These agents leverage dual antigen engagement to orchestrate potent immune responses, while novel immunomodulatory drugs harness a blend of anti-inflammatory and anti-tumor activities. Proteasome and histone deacetylase inhibitors continue to occupy central roles, but their integration into optimized combination regimens is driving deeper, more durable remissions.

Collectively, these developments signal a paradigm shift from sequential monotherapies to strategically engineered combination and cell-based regimens. Emerging data suggest that earlier deployment of highly potent modalities can prolong survival and improve quality of life, creating momentum for accelerated approval pathways and broader global access.

Assessing the Impact of New United States Tariffs on Treatment Access

Anticipated tariff adjustments in the United States commencing in 2025 are poised to exert significant influence on drug pricing, supply chain logistics, and overall patient access. Manufacturers face heightened cost pressures as import duties on critical components and finished biologics could drive up overhead and force recalibration of pricing strategies. In response, some stakeholders are exploring onshore manufacturing partnerships and regional production hubs to mitigate incremental expenses and ensure supply stability.

Payers and health systems are preparing for potential budgetary constraints, with formulary committees reevaluating cost-effectiveness thresholds. Higher list prices may prompt increased reliance on value-based contracting and outcomes-based agreements to align reimbursement with real-world performance. Patient assistance programs will likewise need expansion to cushion end-user costs and maintain adherence rates.

Regulatory agencies and industry coalitions are engaging in policy dialogues to soften tariff impacts, advocating for exemptions on vital therapies or phased implementations. As the landscape evolves, proactive collaboration among manufacturers, policymakers, and providers will be critical to preserve innovation incentives while safeguarding equitable access.

Unpacking Key Segmentation Dynamics Driving Strategic Insights

An in-depth segmentation lens reveals critical pathways for targeted innovation and market positioning. When classified by drug class, the field comprises five pillars: CAR-T cell therapies encompassing Ciltacabtagene Autoleucel and Idecabtagene Vicleucel; histone deacetylase inhibitors represented by Panobinostat and Vorinostat; the suite of immunomodulatory agents including Lenalidomide, Pomalidomide, and Thalidomide; monoclonal antibodies such as Daratumumab, Elotuzumab, and Isatuximab; and proteasome inhibitors like Bortezomib, Carfilzomib, and Ixazomib. Each class exhibits distinct efficacy profiles, safety considerations, and manufacturing complexities that shape therapeutic choice.

Treatment line segmentation further refines strategic targeting. First-line approaches balance combination regimens and monotherapies, with Bortezomib Lenalidomide Dexamethasone and Carfilzomib Lenalidomide Dexamethasone driving deep remissions alongside Daratumumab and Lenalidomide monotherapy options. In second-line settings, combination therapies such as Carfilzomib Pomalidomide Dexamethasone and Pomalidomide Bortezomib Dexamethasone compete with single-agent Daratumumab and Pomalidomide, each calibrated for resistant disease. Third-line and beyond has become a frontier for bispecific antibodies and advanced CAR-T constructs, marking a shift toward aggressive intervention in refractory cases.

The mode of administration adds another dimension, with intravenous infusions, oral regimens, and subcutaneous injections offering variable convenience, adherence, and healthcare resource implications. Distribution channels span hospital pharmacies, retail outlets, and specialized dispensing centers, each influencing patient touchpoints and reimbursement pathways. Finally, the distinction between branded and generic products underpins competitive dynamics, margin structures, and lifecycle management strategies across the therapeutic continuum.

Illuminating Market Patterns Across Key Geographies

Regional analysis highlights differentiated growth drivers and adoption patterns across major global markets. The Americas region retains leadership through robust R&D funding, well-established reimbursement frameworks, and early adoption of cutting-edge therapies. North America in particular benefits from a dense network of transplant centers and a high level of stakeholder collaboration that accelerates clinical translation.

In Europe, Middle East & Africa, a mosaic of regulatory environments shapes therapy uptake. Established markets in Western Europe maintain strong demand for novel agents, while emerging markets in Eastern Europe, the Gulf region, and Africa face infrastructure and affordability challenges. Strategic partnerships and local manufacturing initiatives are proving instrumental in bridging access gaps and fostering sustainable uptake.

Asia-Pacific has emerged as a dynamic growth engine fueled by demographic trends, increasing healthcare expenditure, and expanding clinical trial activity. Markets in Japan, China, and Australia are rapidly integrating advanced therapies, supported by streamlined approval pathways and government incentives. Continued investment in capacity building and reimbursement reforms will be pivotal to sustaining momentum across the broader region.

Profiling Strategic Initiatives of Leading Market Players

Leading biopharmaceutical companies are executing multifaceted strategies to strengthen their position in the multiple myeloma space. Major players with expansive pipelines are pursuing collaborations with emerging biotech innovators to co-develop next-generation cell therapies and bispecific platforms. At the same time, internal investment in manufacturing capacity and quality systems is enabling consolidation of production footprints for high-value biologics.

Strategic licensing agreements and milestone-based partnerships have become commonplace, providing access to novel modalities while sharing development risk. Meanwhile, established firms are optimizing their product portfolios through life-cycle management initiatives, including label expansions, novel formulation developments, and combination therapy trials. Diversification into oral and subcutaneous administration routes aims to enhance patient convenience and reduce the burden on infusion centers.

Competitive differentiation is increasingly driven by targeted real-world evidence programs and payer engagement frameworks. Companies are leveraging health economics and outcomes research to substantiate value propositions, while digital platforms and patient support services reinforce adherence and holistic care. In this dynamic ecosystem, agility and cross-disciplinary collaboration emerge as hallmarks of successful industry leadership.

Actionable Strategies to Capitalize on Emerging Therapeutic Trends

Industry leaders should prioritize investment in advanced immune-based modalities, recognizing that early entry into bispecific antibody and CAR-T segments can yield disproportionate clinical and commercial returns. Building scalable manufacturing capabilities-both in-house and through strategic alliances-will mitigate cost volatility and ensure supply chain resilience.

Expanding patient access requires innovative pricing models aligned with therapeutic outcomes. Stakeholders can explore outcomes-based contracts and risk-sharing agreements to demonstrate real-world value and facilitate reimbursement approvals. Concurrently, strengthening partnerships with advocacy groups and payers will accelerate pathway optimization and reimbursement negotiations.

To maximize market penetration, companies should deploy targeted engagement strategies that leverage predictive analytics to identify patient cohorts likely to derive the greatest benefit. Integrating digital health tools and telemedicine initiatives can enhance monitoring, adherence, and patient support, while generating valuable real-world insights that inform continuous product improvement.

Rigorous Methodology Underpinning Insights and Analysis

This analysis is underpinned by a rigorous methodology combining primary qualitative interviews with leading oncologists, key opinion leaders, and payers, alongside comprehensive secondary research. Data sources include peer-reviewed journals, clinical trial registries, regulatory filings, and corporate financial disclosures. Each data point has been validated through cross-referencing and triangulation to ensure consistency and reliability.

Market segmentation frameworks were developed to capture the full spectrum of therapeutic classes, treatment lines, administration routes, distribution channels, and product types. Regional insights were derived from country-level analyses of clinical adoption rates, reimbursement landscapes, and healthcare infrastructure indices. Competitive intelligence was gathered through strategic pipeline reviews and public domain monitoring of corporate developments.

All projections and trend analyses reflect the latest regulatory updates, clinical trial outcomes, and policy shifts. This methodological approach ensures that conclusions and recommendations are grounded in robust evidence, providing stakeholders with high-confidence guidance for strategic planning and investment decisions.

Concluding Perspectives on Future Therapeutic Frontiers

As the multiple myeloma therapeutic ecosystem continues to evolve, the convergence of cellular therapies, novel biologics, and precision medicine underscores a trajectory toward more effective and personalized care. Ongoing innovations will likely redefine treatment paradigms, with earlier intervention strategies and combination regimens that prolong survival and optimize quality of life.

The interplay of policy dynamics, pricing pressures, and regional access variations will shape the pace of adoption and the realization of clinical benefits. Forward-looking stakeholders must remain vigilant to shifts in regulatory frameworks and tariff environments, while sustaining investment in R&D and market access capabilities.

Ultimately, the capacity to harness emerging scientific breakthroughs, align evidence generation with value demonstration, and engage collaboratively across the healthcare continuum will determine which organizations lead the next chapter in multiple myeloma care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • CAR-T Therapy
      • Ciltacabtagene Autoleucel
      • Idecabtagene Vicleucel
    • Histone Deacetylase Inhibitor
      • Panobinostat
      • Vorinostat
    • Immunomodulatory Drug
      • Lenalidomide
      • Pomalidomide
      • Thalidomide
    • Monoclonal Antibody
      • Daratumumab
      • Elotuzumab
      • Isatuximab
    • Proteasome Inhibitor
      • Bortezomib
      • Carfilzomib
      • Ixazomib
  • Treatment Line
    • First Line
      • Combination Therapy
        • Bortezomib Lenalidomide Dexamethasone
        • Carfilzomib Lenalidomide Dexamethasone
      • Monotherapy
        • Daratumumab Monotherapy
        • Lenalidomide Monotherapy
    • Second Line
      • Combination Therapy
        • Carfilzomib Pomalidomide Dexamethasone
        • Pomalidomide Bortezomib Dexamethasone
      • Monotherapy
        • Daratumumab Monotherapy
        • Pomalidomide Monotherapy
    • Third Line And Beyond
      • Bispecific Antibodies
      • CAR-T Therapy
  • Mode Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
    • Specialty Pharmacy
  • Product Type
    • Branded
    • Generic
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Karyopharm Therapeutics Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multiple Myeloma Therapeutics Market, by Drug Class
8.1. Introduction
8.2. CAR-T Therapy
8.2.1. Ciltacabtagene Autoleucel
8.2.2. Idecabtagene Vicleucel
8.3. Histone Deacetylase Inhibitor
8.3.1. Panobinostat
8.3.2. Vorinostat
8.4. Immunomodulatory Drug
8.4.1. Lenalidomide
8.4.2. Pomalidomide
8.4.3. Thalidomide
8.5. Monoclonal Antibody
8.5.1. Daratumumab
8.5.2. Elotuzumab
8.5.3. Isatuximab
8.6. Proteasome Inhibitor
8.6.1. Bortezomib
8.6.2. Carfilzomib
8.6.3. Ixazomib
9. Multiple Myeloma Therapeutics Market, by Treatment Line
9.1. Introduction
9.2. First Line
9.2.1. Combination Therapy
9.2.1.1. Bortezomib Lenalidomide Dexamethasone
9.2.1.2. Carfilzomib Lenalidomide Dexamethasone
9.2.2. Monotherapy
9.2.2.1. Daratumumab Monotherapy
9.2.2.2. Lenalidomide Monotherapy
9.3. Second Line
9.3.1. Combination Therapy
9.3.1.1. Carfilzomib Pomalidomide Dexamethasone
9.3.1.2. Pomalidomide Bortezomib Dexamethasone
9.3.2. Monotherapy
9.3.2.1. Daratumumab Monotherapy
9.3.2.2. Pomalidomide Monotherapy
9.4. Third Line and Beyond
9.4.1. Bispecific Antibodies
9.4.2. CAR-T Therapy
10. Multiple Myeloma Therapeutics Market, by Mode of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Multiple Myeloma Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Retail Pharmacy
11.4. Specialty Pharmacy
12. Multiple Myeloma Therapeutics Market, by Product Type
12.1. Introduction
12.2. Branded
12.3. Generic
13. Americas Multiple Myeloma Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Multiple Myeloma Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Multiple Myeloma Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bristol-Myers Squibb Company
16.3.2. Johnson & Johnson
16.3.3. Takeda Pharmaceutical Company Limited
16.3.4. Amgen Inc.
16.3.5. Sanofi S.A.
16.3.6. GlaxoSmithKline plc
16.3.7. Karyopharm Therapeutics Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MULTIPLE MYELOMA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. MULTIPLE MYELOMA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. MULTIPLE MYELOMA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MULTIPLE MYELOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CILTACABTAGENE AUTOLEUCEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IDECABTAGENE VICLEUCEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PANOBINOSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY VORINOSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ELOTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ISATUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB LENALIDOMIDE DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB LENALIDOMIDE DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DARATUMUMAB MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY LENALIDOMIDE MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB POMALIDOMIDE DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY POMALIDOMIDE BORTEZOMIB DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DARATUMUMAB MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY POMALIDOMIDE MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 102. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 104. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 105. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 106. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 107. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 108. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 109. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 110. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 111. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 112. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 113. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 114. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 115. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 116. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 121. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 122. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 123. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 124. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 125. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 126. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 127. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 128. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 129. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 130. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 131. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 132. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 133. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 207. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 208. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 209. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 210. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 211. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 212. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 213. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 214. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 215. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 216. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 217. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 218. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 219. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 224. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 225. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 226. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 227. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 228. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 229. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 230. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 231. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 232. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 233. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 234. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 235. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 236. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 258. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 259. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 260. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 261. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 262. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 263. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 264. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 265. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 266. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 267. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 268. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 269. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 270. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 273. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 274. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 275. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 276. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 277. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 278. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 279. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 280. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 281. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 282. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 283. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 284. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 285. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, 2018-2030 (USD MILLION)
TABLE 286. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2030 (USD MILLION)
TABLE 287. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, 2018-2030 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2030 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES M

Companies Mentioned

The companies profiled in this Multiple Myeloma Therapeutics market report include:
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Karyopharm Therapeutics Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 24.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 34.76 Billion
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Multiple Myeloma Therapeutics Market Size, Share & Trends Analysis Report By Drug, By Disease (Active Multiple Myeloma, Smoldering Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Multiple Myeloma Therapeutics Market Size, Share & Trends Analysis Report By Drug, By Disease (Active Multiple Myeloma, Smoldering Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 80 Pages
  • Global
From
Multiple Myeloma Therapeutics - Global Strategic Business Report - Product Image

Multiple Myeloma Therapeutics - Global Strategic Business Report

  • Report
  • 293 Pages
  • Global
From
Multiple Myeloma Drugs Market Report by Therapy, Drug Type, End-User, Distribution Channel, and Region 2024-2032 - Product Image

Multiple Myeloma Drugs Market Report by Therapy, Drug Type, End-User, Distribution Channel, and Region 2024-2032

  • Report
  • 138 Pages
  • Global
From
Multiple Myeloma Drugs Market Report 2025 - Product Image

Multiple Myeloma Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Multiple Myeloma Drug Market by Drug Class, Line of Therapy, Treatment Regimen, Route of Administration, Distribution Channel, Patient Age, Gender - Global Forecast to 2030 - Product Image

Multiple Myeloma Drug Market by Drug Class, Line of Therapy, Treatment Regimen, Route of Administration, Distribution Channel, Patient Age, Gender - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.